“A randomized double-blinded trial to assess recurrence of systemic allergic reactions following COVID-19 mRNA vaccination”

https://www.sciencedirect.com/science/article/pii/S0091674924002367?utm_campaign=+59950531&utm_content=&utm_medium=email&utm_source=govdelivery&utm_term= A small NIAID clinical trial has found that receiving second and booster doses of a COVID-19 mRNA vaccine under medical supervision was safe for people who reported a systemic allergic reaction to their first dose. After revaccination, 12.5% of study participants had a systemic allergic reaction, while 62.5% had a non-allergic reaction that mimics anaphylaxis and is called Immunization Stress-Related Response (ISRR). These findings highlight the opportunity to assess and manage pre-vaccination anxiety to reduce ISRR. The results are published in the Journal of Allergy and Clinical Immunology.